Dr. Singh on Investigational Immunotherapy Combinations in Urothelial Cancer

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses investigational immunotherapy combinations in urothelial cancer.

Combination strategies are emerging, says Singh. At the 2019 ASCO Annual Meeting, Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, presented data regarding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in previously treated patients with metastatic disease. The expansion cohort results of the phase I/II CheckMate-032 trial showed that the objective response rate was 38.0% in patients who received 3 mg/kg of nivolumab and 1 mg/kg of ipilimumab.

In addition to combinations of double immunotherapy agents, combinations of immunotherapy and antibody-drug conjugates and chemotherapy are being explored. These combinations may broaden the utility of immunotherapy in the field to targeted agents such as erdafitinib (Balversa) and enfortumab vedotin, says Singh.